Feedback
Settings

Settings

Goto Application

257 results
Offices all Languages Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

CHEM:(MSGFOEBMIJOVCL-VPCXQMTMSA-N)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 26
1.WO/2026/082097POLYPEPTIDE, RNA MOLECULE AND MEDICAL USE THEREOF
WO - 23.04.2026
Int.Class C07K 14/515
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
475Growth factors; Growth regulators
515Angiogenic factor; Angiogenin
 Appl.No PCT/CN2025/128012 Applicant SHANGHAI REGENELEAD THERAPIES CO., LTD. Inventor ZHANG, Jiao
The present disclosure relates to a polypeptide, an RNA molecule and a medical use thereof, and specifically relates to an ANGPTL polypeptide, an RNA molecule, a polynucleotide, a vector, lipid nanoparticles, a pharmaceutical composition and a medical use thereof.
2.WO/2026/067817NUCLEIC ACID ENCODING THROMBOPOIETIN OR PRECURSOR THEREOF, AND NUCLEIC ACID COMPOSITION
WO - 02.04.2026
Int.Class C12N 15/62
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
62DNA sequences coding for fusion proteins
 Appl.No PCT/CN2025/125637 Applicant ABOGEN LIFE SCIENCES (SHANGHAI) CO., LTD. Inventor DU, Liang
Provided are a nucleic acid encoding thrombopoietin or a precursor thereof, and a composition and kit comprising same. Further provided is a use of the nucleic acid, the composition and the kit in treatment of thrombocytopenia.
3.121752579乙基修饰的RNA帽和使用方法
CN - 27.03.2026
Int.Class C07H 21/02
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
21Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
02with ribosyl as saccharide radical
 Appl.No 202480055120.3 Applicant 胡桃夹子治疗公司 Inventor C·J·麦金来
本文提供了作为带有N‑乙基鸟苷部分的多核苷酸(例如，RNA分子，诸如mRNA分子)的帽类似物的化合物。还提供了加帽的多核苷酸，例如加帽的RNA分子，诸如加帽的mRNA分子，其中RNA分子的5’末端包含本文公开的帽类似物；包含加帽的RNA分子的药物产品；用于制备本文公开的加帽的多核苷酸的方法；以及用于制备加帽的多核苷酸的试剂盒。(I)
4.121729225具有增强药物应用的特定表面活性剂性质的稳定脂质和类脂质纳米颗粒制剂
CN - 24.03.2026
Int.Class A61K 9/52
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
9Medicinal preparations characterised by special physical form
48Preparations in capsules, e.g. of gelatin, of chocolate
52Sustained or differential release type
 Appl.No 202480054649.3 Applicant 埃泽瑞斯公司 Inventor E·贝古因
本发明提出了用具有特定特征的表面活性剂增强的新型脂质和类脂质纳米颗粒(LNP和LiNP)制剂。这些表面活性剂表现出独特的朗缪尔等温线特性，确保了纳米颗粒的最佳稳定性。所述制剂提高了稳定性，减少了聚集，并缓解了在纯化期间面临的挑战，比如过滤堵塞或结垢。该创新所必需的是基于预定的朗缪尔等温线值和过滤速度确定表面活性剂作为稳定剂的适用性的方法。当与治疗剂一起配制时，稳定的纳米颗粒在医学应用，特别是在mRNA递送、疫苗接种和免疫领域中具有证实的潜力。
5.20260071212GalNAc conjugated oligonucleotides for RNA editing
US - 12.03.2026
Int.Class C12N 15/11
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
 Appl.No 19329194 Applicant KORRO BIO, INC. Inventor Venkat Krishnamurthy

Provided herein are modified oligonucleotides comprising novel GalNAc-containing moieties. Also provided are formulations comprising the modified oligonucleotides disclosed herein, and methods of treating diseases and disorders using the modified oligonucleotides and formulations thereof disclosed herein.

6.20260071215SYSTEMS FOR ENHANCING TARGET MRNA EXPRESSION AND USES THEREOF
US - 12.03.2026
Int.Class C12N 15/113
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
 Appl.No 18873043 Applicant The Johns Hopkins University Inventor Jeffery Coller

Provided herein are nucleic acid agents that are or comprise one or more nucleic acid molecules, together comprising (a) a complementary element that hybridizes with a target mRNA; and (b) a poly(A) element. In some embodiments, the target mRNA is an mRNA of an active allele of a gene associated with a disorder associated with a decrease in the expression of a protein from the mRNA, wherein the disorder is a haploinsufficiency disorder.

7.WO/2026/050243GALNAC CONJUGATED OLIGONUCLEOTIDES FOR RNA EDITING
WO - 05.03.2026
Int.Class A61K 47/54
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
54the modifying agent being an organic compound
 Appl.No PCT/US2025/043523 Applicant KORRO BIO, INC. Inventor KRISHNAMURTHY, Venkat
Provided herein are modified oligonucleotides comprising novel GalNAc-containing moieties. Also provided are formulations comprising the modified oligonucleotides disclosed herein, and methods of treating diseases and disorders using the modified oligonucleotides and formulations thereof disclosed herein.
8.WO/2026/030275RNA MOLECULES
WO - 05.02.2026
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
 Appl.No PCT/US2025/039598 Applicant PFIZER INC. Inventor ALLAJ, Viola
The present disclosure relates to RNA molecules encoding an EBV polypeptide. The present disclosure further relates to compositions comprising the RNA molecules formulated in a lipid nanoparticle (RNA-LNP). The present disclosure further relates to the use of the RNA molecules, RNA-LNPs and compositions for the treatment and/or prevention of infectious mononucleosis, and other diseases associated with EBV infection.
9.20260021175IMMUNOGENIC COMPOSITIONS AND USES THEREOF
US - 22.01.2026
Int.Class A61K 39/155
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
155Paramyxoviridae, e.g. parainfluenza virus
 Appl.No 19270518 Applicant Pfizer Inc. Inventor Bridget Yih Jiin Huang

The present disclosure relates to RSV F, hMPV F, PIV3 F, PIV3 HN, PIV1 F and PIV1 HN protein mutants, nucleic acids or vectors encoding them, compositions comprising a RSV F, hMPV F, PIV3 F, PIV3 HN, PIV1 F and/or PIV1 HN nucleic acid or combinations thereof, and uses thereof.

10.WO/2025/250534T CELL TARGETS FOR TUBERCULOSIS VACCINES
WO - 04.12.2025
Int.Class A61K 39/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
02Bacterial antigens
04Mycobacterium, e.g. Mycobacterium tuberculosis
 Appl.No PCT/US2025/031027 Applicant THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY Inventor DAVIS, Mark M.
The Mtb protein Rv2140c, specific peptide epitopes derived, and polynucleotide sequences encoding such polypeptides are disclosed herein as a useful TB antigen for generating a protective immune response to development of tuberculosis. In some embodiments the Rv2140c polypeptide or polynucleotide is formulated as a vaccine. In some embodiments the Rv2140c vaccine is administered to a naïve recipient. In some embodiments the Rv2140c vaccine is administered as a booster to a previously vaccinated to exposed individual. In some embodiments the previous vaccination is a BCG vaccination.
# -